Altria Group (MO)

Total return at 5 years: 9.9%/year = 3.4% appreciation + 6.5% dividend. The target price ($85) is ex-dividend; the $25 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $106 · Multiples $90) exceeds the market price ($72).

Today — fairly valued: at $72 trades ~20.2% below its value discounted to today (~$90); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($85) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$59.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($72) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-8.3%/year) than we project (0.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$5.2 bn of owner earnings in year 5 (vs ~$8 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on Utilidad neta normalizada (P/E). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Nicotine consumer staple in structural decline: valued on P/E over normalized net income, which gives equity value directly, with no EV→equity bridge. Rolling grid: the base year is the real TTM (revenue of US$23.5 billion as of Jun 30, 2026), with the operating (~47.2%) and net (~34.3%) margins already reasonably clean of most of the non-cash e-vapor impairment ($2.1bn in 2025, after the ITC exclusion order on NJOY). The revenue starting point (−2.1%) is the average of the noisy trajectory FY23 −2.4% · FY24 −1.9% · FY25 −3.1% · TTM −1.1% (not the better stretch: cigarette volume falls −10.0% and price/mix only partly offsets it), decelerating toward −0.5% by year 5 as oral nicotine (on! pouches, +11% volume, already 56.9% of the oral category) weighs more in the mix. Net income stays essentially flat (~$8bn/year): margin expansion (mix toward Oral + cost discipline) offsets almost all of the volume decline. Book equity is negative (−$3.2bn at Mar-2026, from decades of buybacks above retained earnings) — a common trait in mature capital-light compounders, not a sign of insolvency. Buybacks are material (historical net reduction ~2%/year, although the current pace is more modest) → modeled with `sharesPath`. Today's real payout —dividends + buybacks over real FCF— is ~86%, so retention is low (~14%) and only that fraction of the flow accumulates. Exit multiple 16× = the floor of the consumer staples band [16,22×] (base; bear 12× / bull 19×), disciplined by moat erosion (volume, e-vapor, litigation). The dividend (with a progressive growth target through 2028) is the bulk of the return.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $85 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $72, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $85 in 5 years plus $25 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $90. Against the current market price ($72), the margin of safety is 20.2% (trades below the maximum → there is margin) and the total return at that price would be 9.9% annually.

• Multiple vs. quality. P/E of 15× against a quality-staples band of 16-22x — the discount genuinely reflects risk (litigation, decline); it is not entirely free.
• Reverse DCF. The price already discounts essentially flat to slightly declining earnings — consistent with the base case, without requiring a heroic turnaround of the business.
• Margin of safety. The total return (mostly dividend, 6.2% yield) falls within the method's average-return range — attractive on a cash basis, without being an obvious bargain.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ✓ CFROIC backs up the ROIC (99%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC exceeds the cost of capital. ROIC ~46% (on real invested capital: debt + negative equity − cash ≈ $17.9bn) vs. the 10% bar — a capital-light business with an extremely high return.
• Margin and stability. Operating margin ~47%, among the highest of any sector — but GAAP earnings are volatile due to impairments and non-recurring gains (IQOS 2024).
• Cash quality. Actual FCF (~$9.1bn TTM) ≈ net income (~$7.97bn) — minimal capital expenditure, with no need for accruals to sustain the flow. CFROIC (~45.5%) sits just below ROIC (~46%): total capital expenditure runs above book depreciation — with no sign of growth capital expenditure in a business with declining volume — but the gap is minimal.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The engine of a mature nicotine business is volume × price/mix: cigarette volume is falling sharply (shipments −10.0% in 2025) while price/mix only partially offsets it in reported revenue (−3.1% FY2025). The oral nicotine pouch category (on!) is the only line with genuine volume growth (+11% in 2025, already 56.9% of oral tobacco) and increasingly offsets the combustible segment. The dividend, declared annually, sustains a policy of progressive growth (targeting mid-single digits through 2028).

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. Revenue declines in both real and nominal terms — there is no FX distortion (a 100% domestic business) nor inflation masking a real decline.
• Growth engine. The only genuine growth engine is oral nicotine (on!, +11% volume); cigarettes and, currently, e-vapor as well are a drag.
• Deceleration and cycle. The revenue decline eases over time in the base case (from −2.1% to −0.5%) as Oral carries more weight in the mix, with no reacceleration expected.

• Relevant in 10 years (recurrence). Recurring consumption, but the combustible category is in structural decline; relevance is migrating toward oral nicotine (on!), with mixed execution in vapor so far.
• Pricing power. Strong in the combustible segment (price/mix offsets much of the volume decline), but the risk persists that elasticity and migration toward discount brands (31.8% share, +2.2pp) erode it.
• Moat and its direction. Marlboro brand + regulatory barrier + distribution scale, but the direction is erosion: volume −10%, illicit vapor competition, and the NJOY setback (ITC exclusion order).
• Capital cycle. Mature sector, with no significant new capital entering (high regulatory/legal barriers); the risk is not capital competition but the secular decline of the core category.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)9.2x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 99% of ROIC
• ✓Value creation (ROIC − 10% bar)+36pp
• !Malinvestment test (capex vs incremental ROIC)Strong investment mode 2.0x
• ✓Float / working capitalFrees up cash $0 bn (float / negative WC)
• ✓Dilution (SBC % of revenue + shares)SBC 0.0% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Gross debt ~$24.6bn (net ~$21.1bn); book equity is negative due to decades of buybacks, common in mature capital-light compounders.
• Coverage and cash. Real FCF ~$9.1bn covers the dividend ($7.1bn) + buybacks ($0.7bn) at a ~86% payout — little additional cushion, but debt interest (~$1.2bn) is covered with ample room.
• Legal contingencies. Litigation of large nominal magnitude (RICO, antitrust certified Feb-2026, Master Settlement Agreement NPM adjustments) not quantified on the balance sheet.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. Insiders <1.5% as a group; the largest shareholder is BlackRock (7.56%, passive institutional). No control block, but the Chair is independent of the CEO.
• Capital allocation. Progressive dividend (mid-single-digit annual growth target through 2028) as the overwhelming priority (~78% of real cash flow), with modest buybacks ($735M TTM, $2.0bn authorization through 2026). No significant recent M&A following the NJOY setback (acquired in 2023).
• Integrity / normalization. The e-vapor impairments (~$2.1bn in 2025) are disclosed and explained with a concrete cause (the ITC order); the company's own non-GAAP adjusted earnings are consistent with the normalization applied here.

• A case of missing buyers: the structural ESG exclusion of a 'sin stock' shrinks the base of institutional buyers whose mandates bar them from holding tobacco.
• A case of motivated sellers: short-term noise — non-cash e-vapor impairments, litigation with large nominal exposure (RICO, antitrust, NPM adjustments) — pushes selling beyond what the underlying cash generation would suggest.
• GAAP volatility (impairments, the one-time IQOS gain in 2024) obscures the fact that underlying net income (~$8bn) is relatively stable.

There are identifiable missing buyers and motivated sellers, but there is also genuine risk (volume decline, litigation) that justifies part of the discount — it is not entirely free. The business generates relatively stable earnings despite the GAAP noise, and the dividend (6.2% yield) sustains the return while the noise gets resolved.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at +2%/year (+9% total): the margin of safety protects the downside. The bull (+15%/year, +105% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Volume decline. The structural disconfirming factor: cigarette volume is falling ~10%/year — if price/mix stops offsetting it, earnings enter genuine decline.
• Illicit vapor / NJOY. The ITC exclusion order on NJOY ACE and competition from illicit disposable vapor have already generated ~$2.1bn of impairments in 2025.
• Litigation. RICO, antitrust (class action certified Feb-2026), and Master Settlement Agreement NPM adjustment disputes — of material magnitude, not recognized on the balance sheet.
• Down-trading / discount. The discount category is gaining share (31.8%, +2.2pp) — a sign of consumer income pressure on premium brands.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A slow grower, growing 0% — no conclusive PEG to judge the price.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 9% (EBIT/EV) + ROIC 46% → makes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -8% vs our 0%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -6%/yr, bull-scenario ceiling +10%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: intangibles, efficient scale, cost advantage → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -8%, within what we project (0%) — the story squares with the numbers.